Similarly, the ICER values of SG$418,839/QALY and A$432,197/QALY for osimertinib vs. first-generation EGFR-TKIs in first-line therapy with advanced EGFR-mutant NSCLC in Singapore and Australia were obtained, respectively, which was higher than the then WTP (SG$100,000/QALY and A$50,000/QALY, respectively), revealing to be not cost-effective (Aziz et al., 2020; Khoo and Gao, 2021). This evidence concerns the gene EGFR and non-small cell lung carcinoma.